Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ – Get Free Report) and Stevanato Group (NYSE:STVN – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Health Sciences Acquisitions Co. 2 and Stevanato Group’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Health Sciences Acquisitions Co. 2 | N/A | N/A | -2.38% |
Stevanato Group | 10.47% | 9.86% | 5.79% |
Valuation & Earnings
This table compares Health Sciences Acquisitions Co. 2 and Stevanato Group”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Health Sciences Acquisitions Co. 2 | N/A | N/A | -$380,000.00 | N/A | N/A |
Stevanato Group | $1.09 billion | 6.07 | $157.62 million | €0.47 ($0.48) | 47.81 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Health Sciences Acquisitions Co. 2 and Stevanato Group, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Health Sciences Acquisitions Co. 2 | 0 | 0 | 0 | 0 | 0.00 |
Stevanato Group | 0 | 1 | 5 | 0 | 2.83 |
Risk & Volatility
Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
Insider & Institutional Ownership
89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Stevanato Group beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.
About Health Sciences Acquisitions Co. 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Receive News & Ratings for Health Sciences Acquisitions Co. 2 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Sciences Acquisitions Co. 2 and related companies with MarketBeat.com's FREE daily email newsletter.